A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway and its downstream effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute myeloid leukemia (AML) patients, where it contributes to leukemic cell proliferation, survival, and drug-resistance. Thus, inhibiting mTOR signaling in AML blasts could enhance their sensitivity to cytotoxic agents. Preclinical data also suggest that allosteric mTOR inhibition with rapamycin impaired leukemia initiating cells (LICs) function. In this study, we assessed the therapeutic potential of a combination consisting of temsirolimus [an allosteric mTOR complex 1 (mTORC1) inhibitor] with clofarabine, a nucleoside analogue with potent inhibitory effects on both ribonucleotide reductase and DNA polymerase. The drug combination (CLO-TOR) displayed synergistic cytotoxic effects against a panel of AML cell lines and primary cells from AML patients. Treatment with CLO-TOR induced a G0/G1-phase cell cycle arrest, apoptosis, and autophagy. CLO-TOR was pro-apoptotic in an AML patient blast subset (CD34+/CD38−/CD123+), which is enriched in putative leukemia initiating cells (LICs). In summary, the CLO-TOR combination could represent a novel valuable treatment for AML patients, also in light of its efficacy against LICs.

[1]  C. Lutz,et al.  Identifying leukemia stem cells--is it feasible and does it matter? , 2013, Cancer letters.

[2]  M. Guzman,et al.  Acute myelogenous leukemia stem cells: from Bench to Bedside. , 2013, Cancer letters.

[3]  H. Kantarjian,et al.  The role of clofarabine in acute myeloid leukemia , 2013, Leukemia & lymphoma.

[4]  R. Majeti,et al.  Clonal evolution of acute leukemia genomes , 2013, Oncogene.

[5]  H. Nam,et al.  Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma , 2013, Clinical & Experimental Metastasis.

[6]  J. McCubrey,et al.  Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia , 2012, Leukemia.

[7]  S. Ohtake.  [Current treatment of acute myeloid leukemia]. , 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[8]  R. Arceci,et al.  Clofarabine in pediatric acute leukemia: Current findings and issues , 2012, Pediatric blood & cancer.

[9]  B. Hemmings,et al.  Translation regulation as a therapeutic target in cancer. , 2012, Cancer research.

[10]  A. Ungewickell,et al.  Novel agents in acute myeloid leukemia , 2012, International Journal of Hematology.

[11]  J. McCubrey,et al.  Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels , 2012, Oncotarget.

[12]  M. Tallman,et al.  Remission induction in acute myeloid leukemia , 2012, International Journal of Hematology.

[13]  J. McCubrey,et al.  Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia , 2012, Cell cycle.

[14]  J. Tamburini,et al.  The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia , 2012, Leukemia.

[15]  M. Tallman,et al.  Novel and emerging drugs for acute myeloid leukemia. , 2012, Current cancer drug targets.

[16]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[17]  S. Srivastava,et al.  Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling Glucose regulatory protein 78 and AMPK , 2012, Oncotarget.

[18]  J. McCubrey,et al.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment , 2012, Oncotarget.

[19]  M. Vignetti,et al.  Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML‐1107) , 2012, British journal of haematology.

[20]  L. Galluzzi,et al.  Autophagy is required for the activation of NFκB , 2012, Cell cycle.

[21]  J. McCubrey,et al.  AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications , 2012, Leukemia.

[22]  E. Domany,et al.  Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop , 2011, Cell cycle.

[23]  J. Lippincott-Schwartz,et al.  Mechanisms of mitochondria and autophagy crosstalk , 2011, Cell cycle.

[24]  L. Créancier,et al.  Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience , 2011, Oncotarget.

[25]  Stephen L. Abrams,et al.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells , 2011, Cell cycle.

[26]  D. MacEwan,et al.  Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1 , 2011, Oncotarget.

[27]  J. Turkson,et al.  The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. , 2011, Experimental cell research.

[28]  Stephen L. Abrams,et al.  Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway , 2011, Leukemia.

[29]  A. Simon,et al.  Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia , 2011, Cell cycle.

[30]  L. Platanias,et al.  Targeting mTOR for the treatment of AML. New agents and new directions , 2011, Oncotarget.

[31]  M. J. Ruiz,et al.  Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. , 2011, Blood.

[32]  J. McCubrey,et al.  Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia , 2011, Leukemia.

[33]  S. Sallan,et al.  Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. , 2011, Experimental hematology.

[34]  J. McCubrey,et al.  Preclinical testing of the Akt inhibitor triciribine in T‐cell acute lymphoblastic leukemia , 2011, Journal of cellular physiology.

[35]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[36]  Stephen L. Abrams,et al.  Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy , 2011, Leukemia.

[37]  Liping Wei,et al.  Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. , 2010, Blood.

[38]  J. McCubrey,et al.  Cancer esearch apeutics , Targets , and Chemical Biology ivity of the Novel Dual Phosphatidylinositol 3-Kinase / malian Target of Rapamycin Inhibitor NVP-BEZ 235 R inst T-Cell Acute Lymphoblastic Leukemia , 2010 .

[39]  A. Besson,et al.  Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27Kip1 expression , 2010, Cell cycle.

[40]  D. MacEwan,et al.  FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism , 2010, Oncotarget.

[41]  J. Tamburini,et al.  Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies , 2010, Leukemia.

[42]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[43]  H. Kantarjian,et al.  Clofarabine in leukemia , 2010, Expert review of hematology.

[44]  E. Goncharova,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Abnormal Proliferation and Survival of TSC2-Deficient Cells: Relevance to Pulmonary Lymphangioleiomyomatosis , 2009, Molecular Pharmacology.

[45]  J. Tamburini,et al.  Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. , 2009, Blood.

[46]  E. Estey,et al.  Treatment of acute myeloid leukemia , 2009, Haematologica.

[47]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[48]  J. Tamburini,et al.  Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.

[49]  J. Margolick,et al.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance , 2007, Proceedings of the National Academy of Sciences.

[50]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[51]  D. Levy,et al.  New and Old Functions of STAT3: A Pivitol Target for Individualized Treatment of Cancer , 2005, Cell cycle.

[52]  M. Shimizu,et al.  Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM , 2002, Cancer Chemotherapy and Pharmacology.

[53]  D. Rose,et al.  Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. , 2000, Blood.